Our AI-based approach is designed to:
- Enhance R&D efficiencies
- Shorten development timelines
- Increase probability of success
Nov 14, 2024
BioXcel Therapeutics Reports Third Quarter 2024 Financial ResultsVIEW RELEASE
Nov 12, 2024
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s DementiaVIEW RELEASE
Nov 08, 2024
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024VIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Nov 20, 2024 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
0.588
CHANGE
-0.0147 (-2.44%)